APGE
APGE
US03770N1019
Apogee Therapeutics, Inc.
Loading chart...

Company Profile

-

Latest News

Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth?
APGEABBV
Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout
APGE
Is Apogee Therapeutics (APGE) Fully Priced, Or Still A Bargain?
APGE
Is Apogee Therapeutics Inc. (APGE) Stock Outpacing Its Medical Peers This Year?
APGE

Related stocks

BMRN
BMRN • United States
BioMarin Pharmaceutical Inc.
54.8 USD
10.61B USD 1Y +0.4%
CYTK
CYTK • United States
Cytokinetics, Incorporated
62.91 USD
8.75B USD 1Y +2%
KRYS
KRYS • United States
Krystal Biotech, Inc.
331.61 USD
9.82B USD 1Y +74.9%
CORT
CORT • United States
Corcept Therapeutics Incorporat
121.19 USD
13.1B USD 1Y +34%
IONS
IONS • United States
Ionis Pharmaceuticals, Inc.
45.28 USD
7.52B USD 1Y -38.1%
CRNX
CRNX • United States
Crinetics Pharmaceuticals, Inc.
84.95 USD
9.01B USD
IBRX
IBRX • United States
ImmunityBio, Inc.
10.51 USD
11.14B USD 1Y +291.7%
EXEL
EXEL • United States
Exelixis, Inc.
59.86 USD
14.83B USD 1Y +52.7%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
4 Metrics
Country
United States
Region
North America
Sector
Healthcare
Industry
Biotechnology

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

6/7 High
3Y Volatility
-
Max Drawdown (3Y)
-
Sharpe Ratio (3Y)
-
Beta Factor
0.33
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
ende